Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib

Author： Koh Youngil   Kim Inho   Yoon Sung-Soo   Kim Byoung   Kim Dae-Young   Lee Je-Hwan   Lee Kyoo-Hyung   Park Eunkyung   Kim Hyeoung-Joon   Sohn Sang   Joo Young   Kim Seok   Chung Jooseop   Shin Ho-Jin   Kim Sung-Hyun   Kim Chul   Song Hong   Kim Min   Hyun Myung   Ahn Jin   Jung Chul   Park Seonyang  

Publisher： Springer Publishing Company

ISSN： 0939-5555

Source： Annals of Hematology, Vol.89, Iss.7, 2010-07, pp. : 725-731

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Imatinib and beyond—the new CML study IV: A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

By Berger U.  

Annals of Hematology, Vol. 83, Iss. 4, 2004-04 ,pp. : 258-264

Springer Publishing Company

Access to resources Recommend Favorite

Imatinib Mesylate in Chronic Myeloid Leukemia

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study

By Deenik W.   Holt B.   Verhoef G.   Schattenberg A.   Verdonck L.   Daenen S.   Zachée P.   Westveer P.   Smit W.   Wittebol S.   Schouten H.   Löwenberg B.   Ossenkoppele G.   Cornelissen J.  

Annals of Hematology, Vol. 86, Iss. 2, 2007-02 ,pp. : 117-125

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

By Giles F.J.   Feldman E.J.   Roboz G.J.   Larson R.A.   Mamus S.W.   Cortes J.E.   Verstovsek S.   Faderl S.   Talpaz M.   Beran M.   Albitar M.   O'Brien S.M.   Kantarjian H.M.  

Leukemia Research, Vol. 27, Iss. 12, 2003-12 ,pp. : 1091-1096

Elsevier

Access to resources Recommend Favorite

Effects of lower dose of imatinib to CML patients

By Horikoshi A.   Takei K.   Sawada S.  

Leukemia Research, Vol. 27, Iss. 12, 2003-12 ,pp. : 1167-1167

Elsevier

Access to resources Recommend Favorite